NE3107 in Adults With Neurological Symptoms of Long COVID

Launched by BIOVIE INC. · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called NE3107 to see if it can help adults suffering from Long COVID. Long COVID is when people continue to feel unwell long after their initial COVID-19 infection, experiencing symptoms like fatigue and "brain fog," which makes it hard to concentrate or remember things. In this study, researchers will compare NE3107 to a placebo (a look-alike pill with no medication) to determine if NE3107 can improve these neurological symptoms.

Adults aged 18 to 64 who have been diagnosed with Long COVID and have experienced fatigue and brain fog for at least three months may be eligible to participate. If you join, you would take NE3107 or the placebo twice a day for 84 days and visit the clinic five times for checkups and tests. You would also have a follow-up phone call. It's important to note that you should not have received a COVID-19 vaccination within the last 30 days, and you should not have had severe health issues before getting COVID-19. This study is currently looking for participants, and all genders are welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years to 64 years of age
• • diagnosed with Long COVID with symptoms of fatigue and brain fog for at least 3 months
• • agree to use birth control measures
• • provide voluntary consent
• • willing to allow blood collection
• • pass all screening tests and procedures
• Exclusion Criteria:
• • has received a COVID-19 vaccination within 30 days
• • previous admission to the intensive care unit for COVID-19
• • medical history of major mental or physical illness prior to COVID-19 infection